BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 8813118)

  • 1. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
    Cucco C; Calabretta B
    Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
    Ramachandran C; Wellham LL
    Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
    Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
    Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased 14-3-3ζ expression in the multidrug-resistant leukemia cell line HL-60/VCR as compared to the parental line mediates cell growth and apoptosis in part through modification of gene expression.
    Liang R; Chen XQ; Bai QX; Wang Z; Zhang T; Yang L; Dong BX; Gao GX; Gu HT; Zhu HF
    Acta Haematol; 2014; 132(2):177-86. PubMed ID: 24603438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of multidrug-resistant murine leukemia with antisense mdr1 oligodeoxynucleotides.
    Hiratake S; Azuma E; Nishiguchi Y; Nagai M; Ido M; Komada Y; Sakurai M
    Biomed Pharmacother; 1997; 51(6-7):276-83. PubMed ID: 9309248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition growth of multidrug resistant KBV200 cells by MDR1 antisense RNA.
    Li Y; Wang Y
    Biochem Biophys Res Commun; 1997 Oct; 239(1):345-8. PubMed ID: 9345322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides.
    Alahari SK; Dean NM; Fisher MH; Delong R; Manoharan M; Tivel KL; Juliano RL
    Mol Pharmacol; 1996 Oct; 50(4):808-19. PubMed ID: 8863825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model.
    Gao L; Chen L; Fei XH; Qiu HY; Zhou H; Wang JM
    Chin Med J (Engl); 2006 Jun; 119(11):911-8. PubMed ID: 16780770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ability of selected pyridinium salts to increase the cytotoxic activity of vincristine but not doxorubicin towards sensitive and multidrug resistant promyelocytic leukaemia HL60 cells.
    Maruszewska A; Kostrzewa-Nowak D; Adamus J; Czupryńska K; Maryniak D; Gebicki J; Tarasiuk J
    J Pharm Pharmacol; 2008 May; 60(5):647-53. PubMed ID: 18416942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of antisense oligonucleotides for reversal of multidrug resistance in breast carcinoma cells.
    Gao P; Zhou GY; Lei DP; Zhang XF; Li L; Xu JW; Lin XY
    Cytotherapy; 2007; 9(8):795-801. PubMed ID: 17917879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells.
    Li B; Ye T; Zhao L; Li DH; Gou XH; Zhao LY; Han L; Chen L; Yan LN; Gong JP
    Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):552-9. PubMed ID: 17085341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein.
    Pichler A; Zelcer N; Prior JL; Kuil AJ; Piwnica-Worms D
    Clin Cancer Res; 2005 Jun; 11(12):4487-94. PubMed ID: 15958634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide--doxorubicin conjugate in vitro and in vivo.
    Ren Y; Wang Y; Zhang Y; Wei D
    Mol Pharm; 2008; 5(4):579-87. PubMed ID: 18461970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1.
    Ye X; Liu T; Gong Y; Zheng B; Meng W; Leng Y
    Leuk Res; 2009 Aug; 33(8):1114-9. PubMed ID: 19036441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance.
    Quattrone A; Papucci L; Morganti M; Coronnello M; Mini E; Mazzei T; Colonna FP; Garbesi A; Capaccioli S
    Oncol Res; 1994; 6(7):311-20. PubMed ID: 7865906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells.
    Mutoh K; Tsukahara S; Mitsuhashi J; Katayama K; Sugimoto Y
    Cancer Sci; 2006 Nov; 97(11):1198-204. PubMed ID: 16925584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The relationship between multi-drug resistance gene expression and drug resistance of ovarian carcinoma].
    Zhu L; Lang J; Shen K
    Zhonghua Fu Chan Ke Za Zhi; 1997 Aug; 32(8):462-6. PubMed ID: 9639738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of cancer multidrug resistance by green tea polyphenols.
    Mei Y; Qian F; Wei D; Liu J
    J Pharm Pharmacol; 2004 Oct; 56(10):1307-14. PubMed ID: 15482646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An oligomer complementary to the 5' end region of MDR1 gene decreases resistance to doxorubicin of human adenocarcinoma-resistant cells.
    Corrias MV; Tonini GP
    Anticancer Res; 1992; 12(5):1431-8. PubMed ID: 1444203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.